Published in J Thromb Haemost on August 01, 2006
Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke. Atherosclerosis (2008) 1.05
Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study. Clin Pharmacol Ther (2007) 1.04
Pathway-based genome-wide association analysis of coronary heart disease identifies biologically important gene sets. Eur J Hum Genet (2012) 0.93
Polymorphisms in regulatory regions of cyclooxygenase-2 gene and breast cancer risk in Brazilians: a case-control study. BMC Cancer (2010) 0.88
Association of polymorphisms in cyclooxygenase (COX)-2 with coronary and carotid calcium in the Diabetes Heart Study. Atherosclerosis (2008) 0.87
COX-2 gene promoter polymorphism and coronary artery disease in middle-aged men: the Helsinki sudden death study. Mediators Inflamm (2008) 0.84
No association of nineteen COX-2 gene variants to preclinical markers of atherosclerosis The Cardiovascular Risk in Young Finns Study. BMC Med Genet (2012) 0.78
Association of COX-2 -765G>C genetic polymorphism with coronary artery disease: a meta-analysis. Int J Clin Exp Med (2015) 0.76
The risk of coronary thrombosis with cyclo-oxygenase-2 inhibitors does not vary with polymorphisms in two regions of the cyclo-oxygenase-2 gene. Br J Clin Pharmacol (2011) 0.75
C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA (2001) 15.85
Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med (1996) 8.57
Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA (2001) 5.54
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54
Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA (1997) 4.37
Design of Physicians' Health Study II--a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. Ann Epidemiol (2000) 4.21
Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med (1995) 3.91
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
Light-to-moderate alcohol consumption and risk of stroke among U.S. male physicians. N Engl J Med (1999) 3.21
Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem (2001) 3.12
Mortality and light to moderate alcohol consumption after myocardial infarction. Lancet (1998) 3.06
Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. Circulation (2000) 2.94
Novel clinical markers of vascular wall inflammation. Circ Res (2001) 2.80
Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med (2002) 2.70
Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin Chem (2001) 2.67
Dairy products, calcium, and prostate cancer risk in the Physicians' Health Study. Am J Clin Nutr (2001) 2.64
The primary prevention of myocardial infarction. N Engl J Med (1992) 2.63
A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer (2005) 2.62
Blood pressure and inflammation in apparently healthy men. Hypertension (2001) 2.55
Migraine and cardiovascular disease: a population-based study. Neurology (2010) 2.51
Effect of marathon running on inflammatory and hemostatic markers. Am J Cardiol (2001) 2.50
Adjunctive drug therapy of acute myocardial infarction--evidence from clinical trials. N Engl J Med (1996) 2.48
Domains of axin involved in protein-protein interactions, Wnt pathway inhibition, and intracellular localization. J Cell Biol (1999) 2.36
Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem (1999) 2.35
Discordance between meta-analyses and large-scale randomized, controlled trials. Examples from the management of acute myocardial infarction. Ann Intern Med (1995) 2.31
Systolic and diastolic blood pressure, pulse pressure, and mean arterial pressure as predictors of cardiovascular disease risk in Men. Hypertension (2000) 2.23
The pravastatin inflammation CRP evaluation (PRINCE): rationale and design. Am Heart J (2001) 2.12
The renal effects of nonsteroidal anti-inflammatory drugs in older people: findings from the Established Populations for Epidemiologic Studies of the Elderly. J Am Geriatr Soc (1999) 2.12
Periodontal disease and risk of subsequent cardiovascular disease in U.S. male physicians. J Am Coll Cardiol (2001) 2.11
High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem (2001) 2.06
Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest (1999) 2.03
HbA1c measured in stored erythrocytes and mortality rate among middle-aged and older women. Diabetologia (2007) 2.03
Migraine, headache, and the risk of stroke in women: a prospective study. Neurology (2005) 2.01
Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem (2001) 2.01
Association of common CRP gene variants with CRP levels and cardiovascular events. Ann Hum Genet (2005) 2.00
Large-scale trials of thrombolytic therapy for acute myocardial infarction: GISSI-2, ISIS-3, and GUSTO-1. Ann Intern Med (1993) 1.97
Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med (1992) 1.92
Maternal and paternal history of myocardial infarction and risk of cardiovascular disease in men and women. Circulation (2001) 1.86
Agreement of self-reported migraine with ICHD-II criteria in the Women's Health Study. Cephalalgia (2009) 1.77
Ab initio determination of light hadron masses. Science (2008) 1.74
US Department of Veterans Affairs medical care system as a resource to epidemiologists. Am J Epidemiol (2000) 1.71
Body mass index, migraine, migraine frequency and migraine features in women. Cephalalgia (2009) 1.69
Left ventricular hypertrophy and morphology in familial hypertrophic cardiomyopathy associated with mutations of the beta-myosin heavy chain gene. J Am Coll Cardiol (1993) 1.68
Novel inflammatory markers of coronary risk: theory versus practice. Circulation (1999) 1.65
Parkinson disease and risk of mortality: a prospective comorbidity-matched cohort study. Neurology (2008) 1.63
Height and incidence of cardiovascular disease in male physicians. Circulation (1993) 1.62
D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost (2006) 1.62
Lack of association of C-reactive protein and coronary calcium by electron beam computed tomography in postmenopausal women: implications for coronary artery disease screening. J Am Coll Cardiol (2000) 1.62
Multi-locus candidate gene polymorphisms and risk of myocardial infarction: a population-based, prospective genetic analysis. J Thromb Haemost (2006) 1.61
Prospective study of moderate alcohol consumption and mortality in US male physicians. Arch Intern Med (1997) 1.58
Alcohol consumption and risk of coronary heart disease by diabetes status. Circulation (2000) 1.57
Body mass index and mortality in men: evaluating the shape of the association. Int J Obes (Lond) (2007) 1.57
Prospective evaluation of the angiotensin-converting enzyme insertion/deletion polymorphism and the risk of stroke. Circulation (1999) 1.57
Time urgency and risk of non-fatal myocardial infarction. Int J Epidemiol (2001) 1.55
Diabetes and all-cause and coronary heart disease mortality among US male physicians. Arch Intern Med (2001) 1.55
An overview of trials of cholesterol lowering and risk of stroke. Arch Intern Med (1995) 1.54
Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am J Cardiol (1999) 1.54
Soluble CD40L and cardiovascular risk in women. Circulation (2001) 1.52
Surgical management of carcinoid heart disease. Ann Thorac Surg (1991) 1.50
C-reactive protein gene polymorphisms and the risk of venous thromboembolism: a haplotype-based analysis. J Thromb Haemost (2004) 1.46
Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J (2002) 1.45
Randomised aspirin assignment and risk of adult-onset asthma in the Women's Health Study. Thorax (2008) 1.45
A prospective evaluation of the interleukin-1 receptor antagonist intron 2 gene polymorphism and the risk of myocardial infarction. Thromb Haemost (2001) 1.45
Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology (2004) 1.44
Qualitative and quantitative effects of APOE genetic variation on plasma C-reactive protein, LDL-cholesterol, and apoE protein. Genes Immun (2006) 1.44
Mutation in the promoter region of the beta-fibrinogen gene and the risk of future myocardial infarction, stroke and venous thrombosis. Eur Heart J (2001) 1.44
Usefulness of visceral obesity (waist/hip ratio) in predicting vascular endothelial function in healthy overweight adults. Am J Cardiol (2001) 1.44
A secondary prevention trial of antioxidant vitamins and cardiovascular disease in women. Rationale, design, and methods. The WACS Research Group. Ann Epidemiol (1995) 1.44
Should survivors of myocardial infarction with low ejection fraction be routinely referred to arrhythmia specialists? JAMA (1996) 1.39
Factor V Leiden and recurrent venous thromboembolism. Thromb Haemost (1996) 1.39
A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol (2001) 1.38
Stroke risk predicts verbal fluency decline in healthy older men: evidence from the normative aging study. J Gerontol B Psychol Sci Soc Sci (2001) 1.36
A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther (2010) 1.35
Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate. Am J Epidemiol (1996) 1.34
Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. Ann Intern Med (1991) 1.33
Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. Arterioscler Thromb Vasc Biol (1998) 1.32
Inflammation, infection, and cardiovascular risk: how good is the clinical evidence? Circulation (1998) 1.31
Genetic variation in alcohol dehydrogenase and the beneficial effect of moderate alcohol consumption on myocardial infarction. N Engl J Med (2001) 1.30
Milk intake, circulating levels of insulin-like growth factor-I, and risk of colorectal cancer in men. J Natl Cancer Inst (2001) 1.29
Aspirin in the primary prevention of angina pectoris in a randomized trial of United States physicians. Am J Med (1990) 1.25
Lipid levels and the risk of ischemic stroke in women. Neurology (2007) 1.23
Differential leucocyte count and the risk of future coronary artery disease in healthy men and women: the EPIC-Norfolk Prospective Population Study. J Intern Med (2007) 1.22
Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J Thromb Haemost (2009) 1.22
Migraine and biomarkers of cardiovascular disease in women. Cephalalgia (2007) 1.21
Dietary antioxidants preserve endothelium-dependent vessel relaxation in cholesterol-fed rabbits. Proc Natl Acad Sci U S A (1993) 1.16
Influence of genetic variation in the C-reactive protein gene on the inflammatory response during and after acute coronary ischemia. Ann Hum Genet (2006) 1.14
Migraine and cardiovascular disease: possible mechanisms of interaction. Neurology (2009) 1.14
Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med (1997) 1.13
Analgesic use and renal function in men. JAMA (2001) 1.13
Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: medical office assessment: Writing Group I. Circulation (2000) 1.13
Hypertension and borderline isolated systolic hypertension increase risks of cardiovascular disease and mortality in male physicians. Circulation (1997) 1.11